Superworth

Royalty Pharma PE ratio RPRX

Share price divided by earnings per share over the last twelve months, since 2021.

Today, Nov 3, 2026
38.2×
6-year median
20.5×
Against its 6-year history
99th
percentile: 0 is its lowest day, 100 its highest
6-year range
10.9× to 38.2×
Peer median
38.4×

Royalty Pharma's PE ratio is 38.2× as of Nov 3, 2026: a share price of $67.30 against $1.76 of earnings per share over the last twelve months.

That is above its 6-year median of 20.5×, higher than on 99% of days in the last 6 years.

Over that time it ranged from 10.9× in Dec 2024 to 38.2× in Oct 2026.

The median for 10 healthcare stocks of a similar size is 38.4×.

PE ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far37.8×23.7×38.2×
202523.9×11.3×24.4×
202411.2×10.9×23.6×
2023n/m a value too high to mean anything
202222.1×19.8×22.8×
202120.6×14.3×35.8×

Against its peers

Companies in Healthcare nearest Royalty Pharma's size, closest first, today.

CompanyPE ratio
RPRXRoyalty Pharma38.2×
BIIBBiogen44.3×
GEHCGE HealthCare Technologies18.3×
ONCBeOne Medicines63.2×
IQVIQVIA32.0×
ZTSZoetis13.7×
ILMNIllumina44.0×
MTDMettler-Toledo International38.4×
RMDResMed21.4×
WATWaters118×
MDLNMedlinen/m
Peer median38.4×

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on Royalty Pharma

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.